CELLTOP Clinical Trial: Phase 1 Findings on Adipose-Derived Stem Cell Therapy for Spinal Cord Injury Paralysis

CELLTOP Clinical Trial: Phase 1 Findings on Adipose-Derived Stem Cell Therapy for Spinal Cord Injury Paralysis

Spinal cord injuries (SCI) are life-altering conditions with limited treatment options. While rehabilitation and medical management can provide some improvements, regenerative medicine is emerging as a promising alternative. The CELLTOP study, an on-going multidisciplinary phase 1 study conducted at the Mayo Clinic, is investigating the safety and efficacy of adipose tissue–derived mesenchymal stem cells (AD-MSCs) to aid in spinal cord recovery. 

In this initial report, Bydon et al. describe the outcome of the study’s first treated patient – a 53-year-old survivor of a surfing accident who sustained a high cervical American Spinal Injury Association Impairment Scale grade A SCI with subsequent neurologic improvement that plateaued within 6 months following injury.

The CELLTOP Trial Stem Cell Treatment Process 

Nine months after his injury, the patient enrolled in the CELLTOP study. An abdominal fat tissue sample was collected, and stem cells were isolated, expanded, and preserved. Eleven months after the injury, the patient received an injection of 100 million AD-MSCs through a lumbar puncture at the L3-4 level.

Safety and Tolerability: Minimal Side Effects Observed in Trial

According to the authors, the procedure was well tolerated. The only reported side effect was a mild to moderate headache on the second day, which resolved with over-the-counter medication. No severe adverse effects were observed during the 18-month follow-up.

Observed Neurological Improvements 

Following the stem cell injection, the patient showed notable improvements in motor and sensory function over 18 months, including:

  • Motor Function: The patient’s upper limb motor scores improved from 35 at baseline to 44 at 18 months. Lower limb motor scores increased from 36 to 49. These improvements were observed in both sides of the body.
  • Sensory Function: Sensation, measured through pinprick and light touch scores, nearly doubled. The pinprick score increased from 45 to 95, and the light touch score improved from 54 to 96.
  • Upper Extremity Capabilities: The patient’s ability to use his arms and hands improved significantly, particularly in tasks requiring pulling, pushing, and finger dexterity.
  • Quality of Life: The patient’s physical and mental health scores improved, as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire.

Observed Improvements in Physical Therapy Performance 

Over the 18-month follow-up, the patient also demonstrated significant progress in mobility and strength, including:

  • His walking speed improved from 0.17 m/s to 0.43 m/s.
  • Walking distance increased from 635 feet in 12.8 minutes to 2200 feet in 34 minutes.
  • Shoulder flexibility improved, with greater range of motion in both arms.
  • Grip strength and hand dexterity showed notable gains.

How Stem Cells Aid in Spinal Cord Repair

SCI leads to significant nerve damage and scarring that inhibit natural healing. Stem cells offer potential benefits by:

  • Reducing Inflammation: AD-MSCs have anti-inflammatory properties that may create a more favorable environment for nerve regeneration.
  • Promoting Tissue Repair: These cells can support the growth of new nerve cells and blood vessels, enhancing recovery.
  • Enhancing Neuroprotection: Stem cells may help preserve existing nerve function and prevent further deterioration.

Future Prospects of Regenerative Medicine for SCI 

While this case study presents promising results, further research is necessary. The CELLTOP study continues to evaluate the effectiveness of stem cell therapy in more patients. Future related studies will explore optimal dosing, timing, and potential combination therapies to enhance recovery further.

Based on these initial results, the authors conclude that regenerative medicine -particularly stem cell therapy – holds significant promise for treating SCI. The first patient in the CELLTOP study demonstrated meaningful neurological improvements, suggesting that AD-MSC therapy could offer new hope for those with SCI. Continued research and clinical trials will determine whether this treatment can become a standard option for spinal cord injury recovery.

Source: Bydon M, Dietz AB, Goncalves S, Moinuddin FM, Alvi MA, Goyal A, Yolcu Y, Hunt CL, Garlanger KL, Del Fabro AS, Reeves RK, Terzic A, Windebank AJ, Qu W. CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury. Mayo Clin Proc. 2020 Feb;95(2):406-414. doi: 10.1016/j.mayocp.2019.10.008. Epub 2019 Nov 27. PMID: 31785831.

Alcoholic Liver Disease (ALD): An Overview and Emerging Treatments

Alcoholic Liver Disease (ALD): An Overview and Emerging Treatments

Alcoholic liver disease (ALD) is a serious global health problem that arises from chronic or binge alcohol consumption. As a chronic liver disease, ALD occurs due to alcohol’s harmful effects on the liver, which is the first organ to metabolize alcohol. This process leads to the production of harmful byproducts that damage liver cells and cause oxidative stress. Over time, this damage triggers inflammation and fibrosis (scarring of the liver), eventually progressing to conditions such as steatosis (fatty liver), steatohepatitis (inflammation and fat accumulation), cirrhosis, and even hepatocellular carcinoma (HCC), a type of liver cancer.

Despite the growing need for effective treatment options, there are currently no FDA-approved therapies specifically for ALD. The only definitive treatments available are alcohol abstinence and liver transplantation, but these options are not always accessible or feasible for all patients. Given the limitations of current treatment options, there is a pressing need for new therapeutic strategies to combat ALD.

Challenges in Current Treatment Approaches

To date, the treatments for ALD primarily focus on managing the symptoms and delaying disease progression until a liver transplant is possible. These supportive therapies aim to reduce oxidative stress, regenerate liver cells, and control inflammation. However, they are not effective for many patients.

Various drugs have been investigated to target the underlying causes of ALD, such as oxidative stress and inflammation. Despite showing promise in preclinical studies, many of these therapies have failed to demonstrate significant benefits in clinical trials. The complexity of ALD and the fact that it often develops alongside other health issues, such as poor nutrition or hepatitis, make it difficult to find a one-size-fits-all solution.

Stem Cell Therapy: A Promising Option

In recent years, stem cell therapy has emerged as a potential treatment for ALD. Among the different types of stem cells, mesenchymal stem cells (MSCs) have shown the most promise due to their ability to regenerate damaged tissue and modulate immune responses. MSCs can be sourced from various tissues such as bone marrow, adipose tissue, and umbilical cord blood. Importantly, the use of MSCs is free from the ethical concerns associated with embryonic stem cells, making them a more attractive option for therapeutic research.

MSCs have been widely studied in the context of liver diseases, including ALD, and have shown positive results in preclinical and clinical trials. These stem cells work by reducing inflammation, promoting liver cell regeneration, and improving overall liver function. Moreover, MSCs secrete factors that contribute to their therapeutic effects. These factors, known as the secretome, contain cytokines, growth factors, and extracellular vesicles (EVs), which can mimic the healing properties of MSCs themselves.

Potential for Cell-Free Therapies

Given the challenges with direct stem cell transplantation, researchers are exploring cell-free approaches, which use the secretome and EVs derived from MSCs. These cell-free therapies could offer many of the same benefits as stem cell therapy without the risks associated with cell transplantation. For instance, the secretome contains anti-inflammatory molecules and other agents that can help regenerate damaged liver tissue, while EVs carry proteins and genetic material that help reduce liver damage.

Several preclinical studies have shown that MSC-derived secretomes and EVs can alleviate the symptoms of liver diseases similar to ALD by reducing oxidative stress and inflammation. However, more research is needed to determine the optimal methods for isolating and administering these factors in a clinical setting. One of the key obstacles is the difficulty in distinguishing between EVs and other natural components in the body, making it challenging to ensure that the right therapeutic agents are delivered to patients.

Current Research and Future Directions

Although MSC-based therapies are still in the early stages of development for ALD, the research to date has been encouraging. Studies in animal models have demonstrated that MSCs and their secreted factors can reduce inflammation, prevent fibrosis, and promote liver regeneration. For example, transplantation of MSCs has been shown to improve liver function in mice with alcohol-induced liver damage, while MSC-derived EVs have been found to enhance liver regeneration by promoting the growth of new liver cells.

Stem Cell Therapy: A Promising Future for Alcoholic Liver Disease

Alcoholic liver disease is a major global health issue, with alcohol consumption contributing to a range of liver disorders that can lead to severe and life-threatening conditions. While current treatment options are limited, advances in stem cell therapy, particularly the use of mesenchymal stem cells, offer new hope for treating ALD. MSCs and their secreted factors have shown potential to reduce liver damage, promote regeneration, and modulate the immune system, making them a promising therapeutic option for ALD.

However, despite the progress in preclinical studies, Han et al. highlight many challenges to overcome before these therapies can be widely adopted in clinical practice. Further research is needed to better understand how MSCs and their secretome work, and to develop safer, more effective treatments for ALD. In the meantime, addressing the root causes of ALD, such as excessive alcohol consumption, remains crucial to reducing the burden of this disease worldwide. With continued research and innovation, MSC-based therapies may one day offer a viable solution for patients suffering from this debilitating condition.

Source: Han J, Lee C, Hur J, Jung Y. Current Therapeutic Options and Potential of Mesenchymal Stem Cell Therapy for Alcoholic Liver Disease. Cells. 2023; 12(1):22. https://doi.org/10.3390/cells12010022

Adipose-Derived Stem Cells: A Promising New Approach for Treating Secondary-Progressive Multiple Sclerosis

Adipose-Derived Stem Cells: A Promising New Approach for Treating Secondary-Progressive Multiple Sclerosis

Multiple sclerosis (MS) is a chronic disease that affects the central nervous system, leading to a range of physical and cognitive impairments. There are different types of MS, with the most common being relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS). RRMS is primarily an inflammatory condition, while SPMS involves a progressive decline due to neurodegeneration. 

While significant advancements have been made in treating RRMS with new medications that target inflammation, treatment options for SPMS remain limited. 

In this study, Fernández et al. aimed to evaluate the safety and feasibility of using adipose-derived mesenchymal stem cells (AdMSCs) in patients with SPMS.

Investigating Stem Cell Therapy for SPMS

Currently, the only approved treatments for SPMS with disease activity are interferon β and mitoxantrone, but their effectiveness is either uncertain or associated with serious side effects. Ocrelizumab has recently been approved for treating PPMS, but effective treatments for SPMS are still lacking.

Recently, stem cells have shown promise in various medical applications, particularly in regenerating damaged tissues and modulating the immune system. Currently, stem cell treatments are approved for conditions like blood disorders and severe burns, but mesenchymal stem cells (MSCs) are still being investigated for other uses. 

Fernandez et al.’s study was conducted in two hospitals in Spain and involved a placebo-controlled, randomized trial. Patients were divided into three groups: one receiving a placebo, another receiving a lower dose of stem cells, and the third receiving a higher dose. To ensure unbiased results, the study was triple-blinded, meaning neither the patients, treating physicians, nor the statisticians analyzing the data knew which treatment each patient received.

The study also required participants to provide 30 grams of adipose tissue for stem cell preparation. Once enrolled, patients received their assigned treatment and were monitored for a year with follow-up visits at 30 days, six months, and twelve months after treatment.

Study Results and Safety Evaluation

A total of 34 patients were initially enrolled in the study. However, four patients were excluded before receiving the treatment due to abnormalities in their stem cell samples. The remaining 30 patients completed the study, with 29 undergoing at least one follow-up assessment. Unfortunately, two patients in the placebo group passed away during the trial—neither death was linked to the stem cell treatment.

Throughout the study, 70 adverse events were reported among 22 patients, with the most common being urinary infections, respiratory infections, and anemia. Four serious adverse events occurred, but only one (a urinary infection) was in a patient who received stem cells. 

Overall, the authors report that there were no major safety concerns related to the treatment. 

Evaluating the Effectiveness of Stem Cell Therapy

To determine whether stem cell therapy had any effect on disease progression, the authors also analyzed various clinical measures, including the Expanded Disability Status Scale (EDSS), MRI scans, and evoked potentials (tests measuring nerve function). 

At the end of the 12-month follow-up, no significant differences were found between the placebo and treatment groups in terms of disability progression. The EDSS scores remained relatively stable in all groups, and MRI scans showed no significant reduction in active lesions or brain volume loss compared to placebo.

Fernández et al. report some positive trends in nerve function tests, particularly in visual evoked potentials, which measure the brain’s response to visual stimuli. Some patients in the treatment groups showed improvements in the speed of their nerve signals, suggesting possible stabilization or mild improvement. However, these changes were not statistically significant when compared to the placebo group.

AdMSC Therapy in SPMS: Findings, Challenges, and Future Directions

This study provides valuable insights into the safety of using AdMSCs in SPMS patients. The treatment was well tolerated, with no major safety concerns.

While there were some encouraging trends in nerve function, Fernández et al. call for larger and longer-term studies to determine whether these changes translate into meaningful clinical benefits. Considering this, the authors call for future research focusing on optimizing stem cell delivery methods, exploring combination therapies, and identifying patient subgroups that may benefit the most from stem cell treatments. 


Source: Fernández O, Izquierdo G, Fernández V, Leyva L, Reyes V, Guerrero M, et al. (2018) Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS ONE 13(5): e0195891. https://doi.org/10.1371/journal.pone.0195891

Exploring Stem Cell Therapy for Progressive Multiple Sclerosis

Exploring Stem Cell Therapy for Progressive Multiple Sclerosis

Progressive multiple sclerosis (PMS) is a complex, disabling form of multiple sclerosis characterized by the progressive accumulation of central nervous system (CNS) damage. This damage arises from chronic inflammation, demyelination, axonal injury, neuronal degeneration, and gliosis, affecting both white and gray matter in the brain and spinal cord. Despite advancements in MS research, effective reparative therapies for reversing the functional impairments associated with PMS remain largely unavailable.

A promising new approach for PMS treatment is NurOwn, a therapy based on mesenchymal stem cell-derived neurotrophic factor (MSC-NTF) cells. NurOwn utilizes a proprietary method to isolate and culture autologous (self-derived) mesenchymal stem cells (MSCs) from bone marrow. These MSCs are then differentiated to secrete high levels of neurotrophic factors (NTFs), which are believed to have both neuroprotective and immunomodulatory properties. Preclinical studies and early clinical trials have suggested that MSC-NTF therapy could help reduce CNS inflammation and promote neuronal repair mechanisms in PMS patients.

Cohen et al.’s open-label phase II study was conducted to evaluate safety/efficacy of three intrathecal cell treatments

Safety and Tolerability of MSC-NTF Therapy

In this Phase II clinical trial (BCT-101), the safety of MSC-NTF therapy was evaluated in 20 participants with PMS, of whom 18 received treatment. While most participants tolerated the therapy well, two discontinued due to adverse events related to the procedure, including mild symptoms such as coldness, muscle weakness, and fever, as well as one case of arachnoiditis -a rare inflammation of the arachnoid membrane surrounding the spinal cord. 

For both affected individuals, MRI scans revealed characteristic lumbar nerve root clumping. Treatment with epidural cortisone and analgesics provided symptom relief, with one participant’s symptoms resolving fully. Importantly, there were no recorded deaths or adverse events associated with MS relapses, and no clinically significant alterations were observed in blood, urinalysis, or vital sign parameters after dosing. 

According to the authors, these results highlight the potential tolerability of MSC-NTF therapy, though further studies are required to assess long-term safety.

Potential of MSC-NTF Therapy for PMS

NurOwn’s MSC-NTF cells have been tested in animal models relevant to PMS, including studies on autoimmune encephalomyelitis and optic nerve damage, which have shown the therapy’s potential to reduce inflammation and support neuroprotective mechanisms. 

Current studies suggest that intrathecal (spinal) administration may offer unique benefits over intravenous administration by directly addressing meningeal inflammation and delivering neurotrophic factors close to the site of CNS damage. The capability of MSC-NTF cells to modulate inflammation and potentially promote endogenous repair makes it a promising therapeutic modality in PMS.

Functional and Biomarker Outcomes

Cohen et al.’s phase II study used several functional outcomes to assess MSC-NTF efficacy in PMS, including the timed 25-foot walk test (T25FW), nine-hole peg test (9-HPT), low-contrast letter acuity (LCLA), and symbol digit modalities test (SDMT). 

Results indicated positive trends in these measures, suggesting that MSC-NTF therapy could improve mobility, hand function, and cognitive speed in PMS patients. Additionally, patient-reported outcomes, such as the MS Walking Scale-12 (MSWS-12), demonstrated improvements in walking function.

Biomarker analysis revealed reductions in cerebrospinal fluid (CSF) inflammatory markers, including MCP-1, sCD27, SDF-1, and osteopontin, indicating a decrease in CNS inflammation. Neuroprotective biomarkers, such as VEGF-A, HGF, NCAM1, and LIF, also showed consistent increases, suggesting that MSC-NTF cells might help support neuronal health and function in PMS. However, changes in neurodegenerative biomarkers, such as neurofilament light chain (NfL), were inconsistent, indicating the need for additional research to understand MSC-NTF’s impact on neuronal damage markers.

Insights and Future Directions Of MSC-NTF Therapy for PMS

This open-label, single-arm Phase II study demonstrated that MSC-NTF cells could be safely administered in participants with stable, non-relapsing PMS. Although two participants experienced arachnoiditis following intrathecal treatment, the majority tolerated the therapy well. Functional outcomes showed encouraging trends, suggesting possible benefits of MSC-NTF therapy in improving physical and cognitive function in PMS patients.

The study also highlighted several limitations, including the lack of a placebo-controlled group, which may introduce bias in interpreting efficacy results, and limitations in biomarker analysis due to sample timing. Additionally, inconsistent changes in neurodegenerative biomarkers and the small sample size warrant further investigation.

In summary, this Phase II trial provides preliminary evidence supporting the safety and potential therapeutic benefits of MSC-NTF cell therapy in PMS. While these initial findings are promising, larger placebo-controlled studies are needed to confirm efficacy and further elucidate the role of MSC-NTF cells in modulating CNS inflammation and promoting neuroprotection in PMS.

Source: Cohen JA, Lublin FD, Lock C, et al. Evaluation of neurotrophic factor secreting mesenchymal stem cells in progressive multiple sclerosis. Multiple Sclerosis Journal. 2023;29(1):92-106. doi:10.1177/13524585221122156

Evaluating Stem Cell Therapy for Degenerative Disc Disease and Low Back Pain

Evaluating Stem Cell Therapy for Degenerative Disc Disease and Low Back Pain

Back pain is the most common cause of disability worldwide, impacting people of all ages and socioeconomic backgrounds. In North America, it is one of the top reasons people miss work and visit doctors. Studies show that at least 80% of Americans will experience low back pain at some point in their lives, making it a major contributor to healthcare costs and lost income, amounting to over $50 billion each year. Although various factors can cause back pain, most cases are mechanical rather than due to an underlying disease. One of the main sources of chronic back pain is the degeneration of intervertebral discs, which can lead to pain in the lower back and neck. Despite its prevalence, there is no standard treatment that effectively restores the normal function of these degenerated discs.

Understanding Disc Degeneration and Back Pain

Degenerative disc disease is one of the most significant contributors to chronic low back pain. As intervertebral discs age or become damaged, they lose their ability to cushion the spine, causing pain and reduced mobility. Degeneration can occur naturally due to aging, but other factors like injury or genetic predisposition can also accelerate the process. While imaging tests such as MRIs can identify disc degeneration, they don’t always pinpoint the exact cause of the pain. This makes treating degenerative disc disease challenging, as doctors struggle to find therapies that not only alleviate pain but also restore disc health.

Emerging Stem Cell Therapies for Back Pain

Recently, regenerative medicine, particularly stem cell therapy, has gained attention as a potential treatment for degenerative disc disease. Stem cells have the ability to transform into different types of cells, making them suitable for repairing damaged tissues. In theory, injecting stem cells into degenerated discs could help regenerate disc tissue and reduce pain.

Overview of Clinical Studies

Several clinical studies have examined the potential of stem cell therapies for treating degenerative disc disease, with mixed results. The types of stem cells studied include:

  • Autologous mesenchymal stem cells (MSCs): These are derived from a patient’s own body, often from bone marrow or fat tissue. Some studies reported a reduction in pain and improvement in quality of life following treatment with MSCs. However, results were inconsistent, and improvements did not always correspond to measurable changes in the disc’s structure.
  • Allogenic stem cells: These are stem cells from donors’ umbilical cord tissue. Research on allogenic stem cells is still limited, with few studies showing significant long-term benefits.
  • Chondrocytes: These cells, which produce cartilage, have also been used in some studies to promote disc regeneration. However, there is limited evidence supporting their use, and more research is needed.

Overall, the studies reviewed had varying degrees of success, with some patients experiencing significant pain relief and others seeing little to no improvement. Many studies lacked control groups or were not randomized, making it difficult to draw definitive conclusions. The most common outcomes measured were pain scores and functional improvements, but there was no clear evidence that stem cell therapy restored the physical structure of degenerated discs.

How Stem Cells Might Work

There are several theories about how stem cells could help regenerate damaged discs. One possibility is that stem cells differentiate into the type of cells needed to repair the disc, such as cells that produce cartilage or other supportive tissues. Another theory is that stem cells create a supportive environment that encourages the body’s own repair mechanisms. For example, animal studies have shown that stem cells can increase the production of molecules that help repair and strengthen disc tissue.

The Future of Stem Cell Therapy for Back Pain

Soufi et al. report that stem cell therapy remains a promising area of research for treating degenerative disc disease. Ongoing clinical trials aim to establish the safety and effectiveness of these treatments in humans, and if successful, could pave the way for a new approach to managing chronic back pain. For stem cell therapy to become a standard treatment, more studies are needed to identify which patients are most likely to benefit and to optimize treatment protocols, including the type and dosage of stem cells.

Researchers are also exploring the use of tissue-engineering technologies and biomaterials to enhance the effectiveness of stem cell therapies. Combining stem cells with supportive scaffolds could improve the chances of successful disc regeneration and provide a more stable environment for cell growth.

The Potential of Stem Cell Therapy for Degenerative Disc Disease and Back Pain

Back pain, particularly when related to degenerative disc disease, is a significant health issue with limited effective treatment options. Stem cell therapy represents a new frontier in regenerative medicine, with the potential to offer relief to patients who have not responded to traditional therapies.

Source: Soufi, K.H.; Castillo, J.A.; Rogdriguez, F.Y.; DeMesa, C.J.; Ebinu, J.O. Potential Role for Stem Cell Regenerative Therapy as a Treatment for Degenerative Disc Disease and Low Back Pain: A Systematic Review. Int. J. Mol. Sci. 2023, 24, 8893. https://doi.org/10.3390/ijms24108893

Clinical Application of Mesenchymal Stem Cells in Autoimmune Conditions

Clinical Application of Mesenchymal Stem Cells in Autoimmune Conditions

The onset of autoimmune diseases is related to unbalanced immune homeostasis and leads to the injury and failure of several organ specific tissues. Currently estimated to affect 8-10% of the population, these autoimmune diseases are associated with serious impairment, high mortality rate, and significant medical costs.

The discovery of stem cells, and specifically mesenchymal stem cells (MSCs), has created new opportunities for accelerating tissue regeneration. MSCs possess the ability to self-renew and differentiate into a wide range of cell types that fill a critical role in immunomodulation and regenerative therapy.  

In this review, Jasim et al. share the latest research on the efficiency and feasibility of MSCs in the clinical treatment of several autoimmune disorders including rheumatoid arthritis, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, liver disease, and Sjogren’s syndrome. 

To date, most of these autoimmune disorders have been treated with a number of conventional drugs, including non-steroidal anti-inflammatory drugs. However, with many of these conditions, these drugs have been observed to contribute to liver injury, gastrointestinal injury, kidney side effects, BM suppression, and psychological disorders, making the development of new and safe therapeutic approaches an important issue. This has led to significant interest in exploring the potential benefits of MSC therapy in treating autoimmune diseases.

MSCs are easily collected from a variety of sources, including umbilical cord (UC), Wharton’s jelly (WJ), adipose tissue, bone marrow (BM), teeth and menstrual fluid. Research has demonstrated that MSCs regulate their local environment, cellular communications, and the release of several factors. MSCs are also able to migrate and differentiate into damaged tissue and can release growth factors, cytokines, and chemokines, which assists in improving tissue regeneration. 

The research evaluated by the authors as part of this review, coupled with MSC’s high proliferation ability, multipotent differentiation capacity, anti-inflammatory and immunomodulatory properties, and regenerative potential, led to the conclusion that there was no remarkable association between mesenchymal stem cell therapy (MSCT) and tumor and infection with the treatment determined to be safe and feasible. 

Jasim et al. also concluded that there is still a lack of understanding of the specific mechanisms through which the MSCT ameliorates these various autoimmune diseases that must be addressed as a way to enhance the future clinical use of MSCs.

Source: Jasim SA, Yumashev AV, Abdelbasset WK, et al. Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases. Stem Cell Res Ther. 2022;13(1):101. Published 2022 Mar 7. doi:10.1186/s13287-022-02782-7

Subscribe To Our Newsletter

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

Request Information Packet

We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!

Thanks for your interest!

Request Information Packet

We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!

Thanks for your interest!

Request Information Packet

We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!

Thanks for your interest!

Request Information Packet

We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!

Thanks for your interest!

Request Information Packet

We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!

Thanks for your interest!

Request Information Packet

We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!

Thanks for your interest!

Request Information Packet

We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!

Thanks for your interest!

Request Information Packet

We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!

Thanks for your interest!

Request Information Packet

We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!

Thanks for your interest!

Request Information Packet

We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!

Thanks for your interest!

Request Information Packet

We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!

Thanks for your interest!

Request Information Packet

We'll send your FREE information packet that outlines our entire personalized, stress-free stem cell treatment process!

Thanks for your interest!